The current propellant in some inhalers is known to have a relatively high global warming potential (GWP) compared to CO2. In this study, AstraZeneca is evaluating a potential alternative propellant, which has a much lower GWP. This study is being conducted to evaluate if a new propellant (the HFO) used in inhalers has a negative effect on the way the lungs clear mucus, when compared to the current inhaler propellant (the HFA)." Please note that AstraZeneca is not responsible for the privacy policy of any third party websites, including this one.
Thank you for your interest, but this study is not currently enrolling.
North Carolina (Statewide)
William Bennett
Center for Environmental Medicine Asthma and Lung Biology (CEMALB)
Clinical or Medical
Interventional
Healthy Volunteer or General Population
22-3306
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
